Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for central nervous system and oncology-related conditions. Its lead candidates, NDV-01 ...

High-risk NMIBC is characterised by poor prognosis, with half of patients recurring despite effective treatment with the ...

The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.